The path to appropriate biosimilar management by Jim Rebello May 10, 2021Biosimilar, Biosimilar Management, Biosimilars, FDA, Magellan Health, Magellan Healthcare, Magellan RX, Magellan Rx Management, Medical Benefit, Oncology Biosimilars, Specialty Pharmacy
2020 FDA Approvals: A Year in Review by Lara Frick March 15, 2021CDER, Center for Drug Evaluation and Research, FDA, FDA Approvals, Food and Drug Administration, Magellan Health, Magellan RX, Magellan Rx Management, New Drugs, Novel agents, Novel drugs, Orphan Drugs
Traditional Drug to Biologic: A Change 10 Years in the Making by Lara Frick June 22, 2020Biologics, Biosimilars, Drug Approvals, FDA, Magellan, Magellan Health, Magellan Healthcare, Magellan RX, Magellan Rx Management, Traditional Drugs
2019 FDA Approvals: A Year in Review by Lara Frick March 19, 2020Biosimilairs, FDA, FDA Approvals, Magellan Health, Magellan RX, Magellan Rx Management, New Drugs, Novel drugs, Orphan Drugs, Trend Alert
Public Health Spotlight – Coronavirus by Maryam Tabatabai February 11, 2020CDC, Coronavirus, Coronavirus prevention, FAQ Coronavirus, FDA, Public Health, WHO
3 Key Trends to Consider for Oncology Management by Rebecca Borgert June 5, 2019Cancer, Cancer treatment, FDA, Magellan, Magellan Health, Magellan Healthcare, Magellan RX, Magellan Rx Management, Medical Benefit Drug Management, Medical Oncology Spend, Novel Cancer Drugs, Oncology, Oncology Biosimilars, Oncology Management
Trend Alert: FDA Approvals – A Year in Review by Lara Frick March 22, 2019Biosimilars, FDA, FDA Approvals, Magellan, Magellan Health, Magellan Healthcare, Magellan RX, Magellan Rx Management, New Drug Therapy Approvals, Novel drugs, Orphan Drugs, Rare Diseases
MRx Pipeline by Maryam Tabatabai November 30, 2018Biosimilars, Drug Pipeline, Emerging therapeutics, FDA, Magellan, Magellan Health, Magellan RX, Magellan Rx Management, MRx Pipeline, Orphan Drugs, Specialty Medications
